TRANSGENE (Euronext Paris: TNG), a biotechnology company that designs and develops cancer immunotherapies based on viral vectors, today announces its participation in several investor conferences.
• The future of Oncology Symposium, Cantor (virtual), 3 – 5 April 2023;
• Investor Access Forum, Paris: April 4–5, 2023;
• Canaccord Genuity Horizons in Oncology Virtual Conference (virtual), April 20, 2023;
• Kempen Van Lanschot Life Sciences Conference, Amsterdam: April 25 – 26, 2023;
• Sachs Annual Immuno-Oncology Innovation Forum, Chicago: June 2, 2023;
• Stifel European Healthcare Summit, Bordeaux: 28 – 30 June 2023.
Transgene will also have a booth (#310) and present several posters at the annual meeting of the AACR (American Association for Cancer Research), which will be held in Orlando, United States, from April 14 to 19, 2023.
…/…